Obesity and hormonal factors in sleep and sleep apnea.
The presence of obesity, defined as weight 20 per cent or more above ideal body weight or increased body fat content, significantly increases risk of pulmonary, cardiovascular, metabolic, and gastrointestinal problems. Obesity is a major cause of shortened life expectancy. While obesity is not essential for the development of the obstructive sleep apnea syndrome, a significant percentage of patients with obstructive sleep apnea are obese. When evaluating these patients who have obstructive sleep apnea, it is important to search diligently for medical problems that are commonly found among the obese. While there is an increased incidence of obese patients among those who have obstructive sleep apnea, the exact reason for this is uncertain. The study of endorphins and enkephalins may expand our understanding of obesity, ventilatory regulation, and obstructive sleep apnea. This may, in fact, enable us to understand better the interrelationship between obesity and obstructive sleep apnea. The role that thyroid hormone, testosterone, and progesterone play in obstructive sleep apnea has also been reviewed. Patients who have obstructive sleep apnea should not be treated with testosterone. All patients given testosterone should be observed quite closely for the possible signs and symptoms of obstructive sleep apnea. Progesterone seems to be of some help in patients who have obesity hypoventilation syndrome. Its effectiveness in patients with obstructive sleep apnea is less clear. The obesity hypoventilation syndrome as described by Burwell is relatively uncommon. Many of the manifestations of the obesity hypoventilation syndrome, however, are found in patients with obstructive sleep apnea. The recognition that the symptoms stem from underlying obstructive sleep apnea offers great potential for therapy. Weight reduction is valuable therapy for patients with obesity and pulmonary dysfunction, obesity and obstructive sleep apnea, and obesity hypoventilation syndrome. Weight reduction and weight maintenance, while difficult, are essential in patients with obesity, obesity and obstructive sleep apnea, and the hypoventilation syndrome. Obesity should be viewed as a medical problem deserving medical attention and long-term medical follow-up.
D000328:Adult; D001810:Blood Volume; D002302:Cardiac Output; D004038:Diet, Reducing; D004723:Endorphins / Q000502:physiology; D004745:Enkephalins / Q000502:physiology; D005260:Female; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D008297:Male; D009230:Myxedema / Q000209:etiology; D009765:Obesity / Q000150:complications / Q000178:diet therapy / Q000503:physiopathology; D010845:Obesity Hypoventilation Syndrome / Q000503:physiopathology; D011374:Progesterone / Q000502:physiology* / Q000627:therapeutic use; D012737:Sex Factors; D012890:Sleep; D012891:Sleep Apnea Syndromes / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D013739:Testosterone / Q000009:adverse effects / Q000378:metabolism / Q000502:physiology*; D013963:Thyroid Hormones / Q000502:physiology* / Q000627:therapeutic use
D004723:Endorphins; D004745:Enkephalins; D013963:Thyroid Hormones; D013739:Testosterone; D011374:Progesterone